Cancer could be a complicated disease that impacts each patient otherwise. Comprehensive and personalized treatment starts with a correct, thorough diagnosing that features radiology, pathology, genetics, and advanced genomics testing. Refined tests and procedures square accustomed to measure the stage and progression of the disease and establish the tumour’s sort, size, and site.

According to WHO Cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018. The most common cancers are Breast Cancer, Lung Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer and Ovarian Cancer.

Cancer arises from the transformation of normal cells into tumour cells in a multistage process that generally progresses from a pre-cancerous lesion to a malignant tumour. These changes are the result of the interaction between a person's genetic factors and 3 categories of external agents, including physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant); and biological carcinogens, such as infections from certain viruses, bacteria, or parasites.

Ageing is another fundamental factor for the development of cancer. The incidence of cancer rises dramatically with age, most likely due to a build-up of risks for specific cancers that increase with age. The overall risk accumulation is combined with the tendency for cellular repair mechanisms to be less effective as a person grows older.

 Cancer diagnosing begins with an intensive physical examination and a whole medical record. Laboratory studies square measure performed to find abnormalities which will indicate cancer. Once a tumour is suspected, imaging tests facilitate doctors to work out cancer's location and size. To verify the diagnosis of the most cancers, a diagnostic test must be performed within which a tissue sample is off from the suspected tumour and studied underneath a magnifier to visualize for cancer cells. If the diagnosing is positive (cancer is present), different tests square measure performed to a supply specific data regarding cancer. If the initial diagnosing is positive for cancer and symptoms persist, additional tests could also be required like Diagnostic Imaging Tests Biopsy and biology Tests, etc.

The cancer diagnostics market is extremely fragmented, with the presence of an outsized variety of natives and international players. Key players adopting completely different growth methods to reinforce their market presence, like partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. For instance, in July 2017, the MEDITE Cancer diagnostics, Inc., proclaimed the launch of SureCyte C1 fluorogenic instant staining product universally. In April 2017, Roche proclaimed the launch of anti-p504s (SP116) Rabbit monoclonal Primary protein, for the identification of prostate cancer. Hence, Cancer Diagnostics Market Set for Rapid Growth During Consequent Years!!!